# NewAmsterdam Pharma Company N.V. (NAMSW)

> Source: Nexqual · https://nexqual.com/NAMSW · data as of 2026-10-13 14:00 UTC · cite as "Nexqual, NewAmsterdam Pharma Company N.V. (NAMSW), nexqual.com/NAMSW" · informational, not investment advice.

**Price:** USD 10.95 (+0.00% on the day) · last close of Oct 13, 2026; US market closed, not a live price. Prev close 10.95 · day 9.79–10.95 · 52w 9.79–30.45 · market cap null · NGM

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $7.1M, net income -$260M (-3644.2% margin), free cash flow -$144M (SEC filings).
- Insider open-market sales, last ~7 months: 6 Form 4 filings, $11.4M; 1 not under a Rule 10b5-1 plan ($41K).
- Total return with dividends: 1Y -56.2% vs S&P 500 +18.1%; 5Y +1695.1% vs S&P 500 +85.1%.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2023 | FY2023 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | — | $103M | $14.1M | $45.6M | $22.5M | $7.1M |
| Operating income | -$35.0M | -$3.6M | -$183M | -$176M | -$226M | -$244M |
| Net income | -$41.8M | -$22.6M | -$177M | -$242M | -$204M | -$260M |
| EPS (diluted) | -$3.81 | -$1.19 | -$2.15 | -$2.56 | -$1.72 | — |
| Free cash flow | -$29.5M | $10.4M | -$141M | -$159M | -$148M | -$144M |
| Operating margin | — | -3.5% | -1298.6% | -386.9% | -1002.9% | -3432.2% |
| Net margin | — | -22.0% | -1255.8% | -530.3% | -905.7% | -3644.2% |
| Revenue growth | — | — | -86.3% | +223.4% | -50.6% | — |
| Cash + short-term investments | — | $468M | $340M | $834M | $636M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)


## Insider sales (SEC Form 4, open-market, last ~7 months)
5 of 6 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan |
|---|---|---|---|---|---|---|
| 2026-09-30 | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | 50,246 | $1.3M | 29% | Yes |
| 2026-09-04 | Smither John W | Director | 1,600 | $41K | 15.4% | No |
| 2026-08-24 | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | 125,000 | $3.4M | 50.4% | Yes |
| 2026-07-20 | Kooij Louise Frederika | Chief Accounting Officer | 105,000 | $3.2M | 81.2% | Yes |
| 2026-06-22 | Kooij Louise Frederika | Chief Accounting Officer | 40,000 | $1.2M | 62.2% | Yes |
| 2026-05-26 | Kooij Louise Frederika | Chief Accounting Officer | 65,000 | $2.3M | 72.7% | Yes |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -56.2% | +1695.1% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -56.3% | +78.0% |
| Volatility (annualized) | 86.9% | 142.3% |
| Max drawdown | -63.5% (May 2026→Oct 2026) | -92.6% (Nov 2021→Jun 2022) |

## Peers
NAMS (NewAmsterdam Pharma Company N.V) USD 20.62 +2.13% · MLECW (Moolec Science SA Warrant) USD 0.01 +20.00% · REVBW (Revelation Biosciences, Inc.) USD 0.01 +1.56% · HUMAW (Humacyte, Inc.) USD 0 -78.05% · OCSAW (Oculis Holding AG Warrants) USD 2.6 +4.42%

## More
Full page: https://nexqual.com/NAMSW · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt